MedTrace Logo

MRI Biomarkers in ALS

NCT02405182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2020-12-07

No results posted yet for this study

Summary

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk factor for developing ALS; thus, the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately measure brain degeneration in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in this respect, and may assist in aiding diagnosis and the efficient testing of new drugs.

Different MRI features of brain degeneration will be measured in a large sample of patients with ALS. The study will operate within the Canadian ALS Neuroimaging Consortium (CALSNIC). CALSNIC is a clinical research platform comprised of ALS clinics with standardized clinical and neuroimaging protocols.

Conditions

Interventions

OTHER

Magnetic Resonance Imaging

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Western University, Canada

    collaborator OTHER

  • McGill University

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Sanjay Kalra, MD, FRCPC · University of Alberta

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-03-31
Completion
2019-04-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02405182 on ClinicalTrials.gov